Plain-English translation of NCT03930732 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our COPD research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested dupilumab, a medication designed to reduce inflammation in the airways of people with moderate-to-severe COPD who experience frequent flare-ups. Researchers studied whether the medication could help these patients breathe better and have fewer disease flare-ups. About 939 patients received either the medication or a placebo (dummy treatment) by injection every two weeks for a full year.
COPD is a serious lung disease where airways become damaged and inflamed, making it hard to breathe. Many people with moderate-to-severe COPD continue to have frequent flare-ups even when taking standard treatments. This trial was designed to see whether this new medication could offer additional relief to those patients.
Participants attended a screening visit, then received injections every two weeks for 52 weeks (either the new medication or placebo). They returned to the clinic regularly so doctors could check how they were doing and watch for any side effects. After the treatment period ended, participants were followed for an additional 12 weeks. The entire study lasted about 68 weeks from start to finish.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States